Natco Pharma Q1 net, revenue slump on lower cancer drug sales
Summary
- Natco Pharma's Q1 net and revenue have declined due to lower sales of cancer drugs.
- The decline is largely attributable to reduced revenue from Lenalidomide.
- The company's shares fell by more than 5% following the announcement.
Key Facts
- · Natco Pharma is a generic drugmaker
- · Lenalidomide is a cancer drug
- · Q1 net and revenue have declined
Why it matters
The decline in sales of cancer drugs can impact the company's financial performance and the availability of affordable medicines.
#Pharmaceuticals#Natco Pharma#Lenalidomide#Generic drugs